QQQ   444.36 (-0.11%)
AAPL   171.69 (-0.93%)
MSFT   420.48 (-0.23%)
META   487.66 (-1.26%)
GOOGL   150.98 (+0.07%)
AMZN   180.30 (+0.26%)
TSLA   176.34 (-1.94%)
NVDA   902.94 (+0.05%)
NIO   4.50 (-3.64%)
AMD   180.28 (+0.38%)
BABA   72.46 (+1.22%)
T   17.63 (+0.46%)
F   13.18 (+0.92%)
MU   117.87 (-1.07%)
CGC   8.52 (-10.79%)
GE   174.91 (-2.89%)
DIS   122.44 (+1.21%)
AMC   3.65 (-15.90%)
PFE   27.87 (+0.32%)
PYPL   67.13 (+0.84%)
XOM   116.09 (+0.97%)
QQQ   444.36 (-0.11%)
AAPL   171.69 (-0.93%)
MSFT   420.48 (-0.23%)
META   487.66 (-1.26%)
GOOGL   150.98 (+0.07%)
AMZN   180.30 (+0.26%)
TSLA   176.34 (-1.94%)
NVDA   902.94 (+0.05%)
NIO   4.50 (-3.64%)
AMD   180.28 (+0.38%)
BABA   72.46 (+1.22%)
T   17.63 (+0.46%)
F   13.18 (+0.92%)
MU   117.87 (-1.07%)
CGC   8.52 (-10.79%)
GE   174.91 (-2.89%)
DIS   122.44 (+1.21%)
AMC   3.65 (-15.90%)
PFE   27.87 (+0.32%)
PYPL   67.13 (+0.84%)
XOM   116.09 (+0.97%)
QQQ   444.36 (-0.11%)
AAPL   171.69 (-0.93%)
MSFT   420.48 (-0.23%)
META   487.66 (-1.26%)
GOOGL   150.98 (+0.07%)
AMZN   180.30 (+0.26%)
TSLA   176.34 (-1.94%)
NVDA   902.94 (+0.05%)
NIO   4.50 (-3.64%)
AMD   180.28 (+0.38%)
BABA   72.46 (+1.22%)
T   17.63 (+0.46%)
F   13.18 (+0.92%)
MU   117.87 (-1.07%)
CGC   8.52 (-10.79%)
GE   174.91 (-2.89%)
DIS   122.44 (+1.21%)
AMC   3.65 (-15.90%)
PFE   27.87 (+0.32%)
PYPL   67.13 (+0.84%)
XOM   116.09 (+0.97%)
QQQ   444.36 (-0.11%)
AAPL   171.69 (-0.93%)
MSFT   420.48 (-0.23%)
META   487.66 (-1.26%)
GOOGL   150.98 (+0.07%)
AMZN   180.30 (+0.26%)
TSLA   176.34 (-1.94%)
NVDA   902.94 (+0.05%)
NIO   4.50 (-3.64%)
AMD   180.28 (+0.38%)
BABA   72.46 (+1.22%)
T   17.63 (+0.46%)
F   13.18 (+0.92%)
MU   117.87 (-1.07%)
CGC   8.52 (-10.79%)
GE   174.91 (-2.89%)
DIS   122.44 (+1.21%)
AMC   3.65 (-15.90%)
PFE   27.87 (+0.32%)
PYPL   67.13 (+0.84%)
XOM   116.09 (+0.97%)
NASDAQ:BJDX

Bluejay Diagnostics (BJDX) Stock Price, News & Analysis

$0.80
0.00 (-0.61%)
(As of 02:10 PM ET)
Today's Range
$0.78
$0.81
50-Day Range
$0.75
$0.92
52-Week Range
$0.73
$13.98
Volume
11,922 shs
Average Volume
51,108 shs
Market Capitalization
$990,884.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Bluejay Diagnostics MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.14% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.44mentions of Bluejay Diagnostics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.62) to ($2.16) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.80 out of 5 stars

BJDX stock logo

About Bluejay Diagnostics Stock (NASDAQ:BJDX)

Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.

BJDX Stock Price History

BJDX Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Why BlueJay Diagnostics Stock Is Falling
Bluejay Diagnostics Prices Offering Of 2.692 Mln Shares At $1.30/shr
BJDX: SYMON Says: Start the Trial! - MSN
BJDX: SYMON Says: Start the Trial!
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Bluejay Diagnostics GAAP EPS of -$2.08
BJDX: Toray License Renegotiation
Blue adVantage Premier (PPO)
True Blue Special Needs Plan (HMO D-SNP)
BJDX: FDA Meeting Confirms Pathway
See More Headlines
Receive BJDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bluejay Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
4/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:BJDX
Fax
N/A
Employees
16
Year Founded
N/A

Profitability

Net Income
$-9,300,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$250,000.00
Book Value
$11.45 per share

Miscellaneous

Free Float
657,000
Market Cap
$994,480.00
Optionable
Not Optionable
Beta
0.81
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Indranil Dey (Age 60)
    President, CEO & Director
    Comp: $413.16k
  • Dr. Jason Cook (Age 41)
    Chief Technology Officer
    Comp: $278.42k
  • Ms. Frances P. Scally (Age 57)
    Interim CFO, Principal Financial Officer & Principal Accounting Officer
  • Mr. Les DeLuca
    Vice President of Operations
  • Eryn Graham
    Marketing Manager
  • Mr. Kevin Vance (Age 67)
    Chief Commercial Officer
  • Mark W. Feinberg
    Chief Medical Advisor
  • Dr. Mark W. Feinberg M.D.
    Chief Medical Advisor
  • Ryan McSeveney
    Corporate Controller

BJDX Stock Analysis - Frequently Asked Questions

Should I buy or sell Bluejay Diagnostics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bluejay Diagnostics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" BJDX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BJDX, but not buy additional shares or sell existing shares.
View BJDX analyst ratings
or view top-rated stocks.

How have BJDX shares performed in 2024?

Bluejay Diagnostics' stock was trading at $1.22 at the start of the year. Since then, BJDX shares have decreased by 34.5% and is now trading at $0.7991.
View the best growth stocks for 2024 here
.

Are investors shorting Bluejay Diagnostics?

Bluejay Diagnostics saw a decrease in short interest during the month of March. As of March 15th, there was short interest totaling 22,000 shares, a decrease of 10.6% from the February 29th total of 24,600 shares. Based on an average daily volume of 68,100 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.1% of the shares of the stock are short sold.
View Bluejay Diagnostics' Short Interest
.

When is Bluejay Diagnostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024.
View our BJDX earnings forecast
.

When did Bluejay Diagnostics' stock split?

Shares of Bluejay Diagnostics reverse split before market open on Monday, July 24th 2023. The 1-20 reverse split was announced on Monday, July 24th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Bluejay Diagnostics IPO?

Bluejay Diagnostics (BJDX) raised $22 million in an IPO on Wednesday, November 10th 2021. The company issued 2,160,000 shares at $10.00 per share.

Who are Bluejay Diagnostics' major shareholders?

Bluejay Diagnostics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (1.95%) and Citadel Advisors LLC (1.78%). Insiders that own company stock include Douglas Clark Wurth, Gordon Winston Kinder and Kenneth R Fisher.
View institutional ownership trends
.

How do I buy shares of Bluejay Diagnostics?

Shares of BJDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BJDX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners